ITRM20030196A0 - Uso di reagenti per la preparazione di un medicamento utile per la terapia perioperatoria in due stadi di tumori solidi. - Google Patents

Uso di reagenti per la preparazione di un medicamento utile per la terapia perioperatoria in due stadi di tumori solidi.

Info

Publication number
ITRM20030196A0
ITRM20030196A0 IT2003RM000196A ITRM20030196A ITRM20030196A0 IT RM20030196 A0 ITRM20030196 A0 IT RM20030196A0 IT 2003RM000196 A IT2003RM000196 A IT 2003RM000196A IT RM20030196 A ITRM20030196 A IT RM20030196A IT RM20030196 A0 ITRM20030196 A0 IT RM20030196A0
Authority
IT
Italy
Prior art keywords
reagents
stages
preparation
solid tumors
medicinal product
Prior art date
Application number
IT2003RM000196A
Other languages
English (en)
Inventor
Giovanni Paganelli
Paolo Carminati
Umberto Veronesi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT000196A priority Critical patent/ITRM20030196A1/it
Publication of ITRM20030196A0 publication Critical patent/ITRM20030196A0/it
Priority to BRPI0409604-5A priority patent/BRPI0409604A/pt
Priority to AU2004231377A priority patent/AU2004231377B2/en
Priority to PL04726249T priority patent/PL1615668T3/pl
Priority to JP2006507647A priority patent/JP4949016B2/ja
Priority to PCT/IT2004/000184 priority patent/WO2004093916A1/en
Priority to EP04726249A priority patent/EP1615668B1/en
Priority to US10/554,410 priority patent/US7935346B2/en
Priority to SI200431974T priority patent/SI1615668T1/sl
Priority to PT47262498T priority patent/PT1615668E/pt
Priority to CNA200480010867XA priority patent/CN1777446A/zh
Priority to ES04726249T priority patent/ES2398389T3/es
Priority to MXPA05011293A priority patent/MXPA05011293A/es
Priority to CA2522580A priority patent/CA2522580C/en
Priority to HRP20121052TT priority patent/HRP20121052T8/hr
Priority to KR1020057019995A priority patent/KR20060005383A/ko
Priority to DK04726249.8T priority patent/DK1615668T3/da
Priority to TW093110125A priority patent/TWI368518B/zh
Priority to ARP040101356A priority patent/AR044052A1/es
Publication of ITRM20030196A1 publication Critical patent/ITRM20030196A1/it
Priority to CY20121101221T priority patent/CY1113488T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IT000196A 2003-04-24 2003-04-24 Uso di reagenti per la preparazione di un medicamento ITRM20030196A1 (it)

Priority Applications (20)

Application Number Priority Date Filing Date Title
IT000196A ITRM20030196A1 (it) 2003-04-24 2003-04-24 Uso di reagenti per la preparazione di un medicamento
DK04726249.8T DK1615668T3 (da) 2003-04-24 2004-04-07 Et lægemiddel til to-trins perioperativ behandling af faste tumorer med radioimmunoterapi
SI200431974T SI1615668T1 (sl) 2003-04-24 2004-04-07 Zdravilo za dvostopenjsko perioperacijsko terapijo trdnih tumorjev z radioimunoterapijo
CNA200480010867XA CN1777446A (zh) 2003-04-24 2004-04-07 用于实体肿瘤二步手术期间治疗的药物
PL04726249T PL1615668T3 (pl) 2003-04-24 2004-04-07 Lek do dwuetapowej terapii okołooperacyjnej nowotworów litych z zastosowaniem radioimmunoterapii
JP2006507647A JP4949016B2 (ja) 2003-04-24 2004-04-07 固形腫瘍の二段階周術期治療のための医薬
PCT/IT2004/000184 WO2004093916A1 (en) 2003-04-24 2004-04-07 A medicament for the two-step perioperative therapy of solid tumours
EP04726249A EP1615668B1 (en) 2003-04-24 2004-04-07 A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy
US10/554,410 US7935346B2 (en) 2003-04-24 2004-04-07 Medicament for the two-step perioperative therapy of solid tumours
BRPI0409604-5A BRPI0409604A (pt) 2003-04-24 2004-04-07 medicamento para a terapia perioperatória em duas etapas de tumores sólidos
PT47262498T PT1615668E (pt) 2003-04-24 2004-04-07 Um medicamento para a terapia perioperatória em dois passos de tumores sólidos
AU2004231377A AU2004231377B2 (en) 2003-04-24 2004-04-07 A medicament for the two-step perioperative therapy of solid tumours
ES04726249T ES2398389T3 (es) 2003-04-24 2004-04-07 Un medicamento para la terapia perioperatoria en dos pasos de tumores sólidos
MXPA05011293A MXPA05011293A (es) 2003-04-24 2004-04-07 Medicamento para la terapia perioperativa de dos etapas de tumores solidos.
CA2522580A CA2522580C (en) 2003-04-24 2004-04-07 A medicament for the two-step perioperative therapy of solid tumours
HRP20121052TT HRP20121052T8 (en) 2003-04-24 2004-04-07 A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy
KR1020057019995A KR20060005383A (ko) 2003-04-24 2004-04-07 고형 종양의 2단계 수술전후 치료를 위한 약물
TW093110125A TWI368518B (en) 2003-04-24 2004-04-12 Use of a medicament for treating and/or controlling local recurrence of solid tumours during and after surgery,and a kit comprising said medicament
ARP040101356A AR044052A1 (es) 2003-04-24 2004-04-22 Medicamentos para la terapia perioperatoria de dos etapas de tumores solidos
CY20121101221T CY1113488T1 (el) 2003-04-24 2012-12-14 Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000196A ITRM20030196A1 (it) 2003-04-24 2003-04-24 Uso di reagenti per la preparazione di un medicamento

Publications (2)

Publication Number Publication Date
ITRM20030196A0 true ITRM20030196A0 (it) 2003-04-24
ITRM20030196A1 ITRM20030196A1 (it) 2004-10-25

Family

ID=29765781

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000196A ITRM20030196A1 (it) 2003-04-24 2003-04-24 Uso di reagenti per la preparazione di un medicamento

Country Status (20)

Country Link
US (1) US7935346B2 (it)
EP (1) EP1615668B1 (it)
JP (1) JP4949016B2 (it)
KR (1) KR20060005383A (it)
CN (1) CN1777446A (it)
AR (1) AR044052A1 (it)
AU (1) AU2004231377B2 (it)
BR (1) BRPI0409604A (it)
CA (1) CA2522580C (it)
CY (1) CY1113488T1 (it)
DK (1) DK1615668T3 (it)
ES (1) ES2398389T3 (it)
HR (1) HRP20121052T8 (it)
IT (1) ITRM20030196A1 (it)
MX (1) MXPA05011293A (it)
PL (1) PL1615668T3 (it)
PT (1) PT1615668E (it)
SI (1) SI1615668T1 (it)
TW (1) TWI368518B (it)
WO (1) WO2004093916A1 (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento
BRPI0815050B8 (pt) * 2007-08-02 2021-05-25 Alfasigma Spa avidina oxidada com tempo de permanência elevado em tecidos tratados, complexo compreendendo a referida avidina e uso dos mesmos, composição farmacêutica, kit, bem como processo de oxidação de avidina
IT1398977B1 (it) 2009-06-25 2013-03-28 Icgeb Agente anticancro specifico per i tumori cerebrali con meccanismo di soppressione di recq1
CN103717239B (zh) * 2011-08-02 2017-08-01 希格马托制药工业公司 适合于吸入的氧化抗生物素蛋白的药物组合物
US20160331853A1 (en) * 2014-01-21 2016-11-17 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
EP3316871A4 (en) * 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
IT1245748B (it) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
DE69433343D1 (de) 1993-12-07 2003-12-24 Neorx Corp Pretargeting verfahren und mitteln
ITRM20010079A1 (it) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
CA2449941A1 (en) 2001-06-11 2002-12-19 University Of Miami Use of radiopharmaceutical complexes in achieving transplantation tolerance
ITRM20020071A1 (it) 2002-02-11 2003-08-11 Sigma Tau Ind Farmaceuti Contenitore per flacone di radiofarmaco, e corredo per la sua infusione in un paziente o per il suo trasferimento altrove.
US20030228256A1 (en) 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
ITRM20030196A1 (it) 2003-04-24 2004-10-25 Sigma Tau Ind Farmaceuti Uso di reagenti per la preparazione di un medicamento

Also Published As

Publication number Publication date
EP1615668A1 (en) 2006-01-18
US20060251579A1 (en) 2006-11-09
JP4949016B2 (ja) 2012-06-06
HRP20121052T1 (hr) 2013-01-31
CA2522580A1 (en) 2004-11-04
AU2004231377A1 (en) 2004-11-04
AR044052A1 (es) 2005-08-24
PL1615668T3 (pl) 2013-03-29
MXPA05011293A (es) 2006-01-24
HRP20121052T8 (en) 2013-03-31
CN1777446A (zh) 2006-05-24
ES2398389T3 (es) 2013-03-15
BRPI0409604A (pt) 2006-04-18
WO2004093916A8 (en) 2005-11-03
SI1615668T1 (sl) 2013-01-31
TW200501984A (en) 2005-01-16
ITRM20030196A1 (it) 2004-10-25
WO2004093916A1 (en) 2004-11-04
PT1615668E (pt) 2013-01-14
CY1113488T1 (el) 2016-06-22
TWI368518B (en) 2012-07-21
EP1615668B1 (en) 2012-12-05
AU2004231377B2 (en) 2010-08-05
KR20060005383A (ko) 2006-01-17
JP2006524235A (ja) 2006-10-26
US7935346B2 (en) 2011-05-03
DK1615668T3 (da) 2013-02-04
CA2522580C (en) 2013-08-06

Similar Documents

Publication Publication Date Title
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
CR8226A (es) Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos
DE602004016967D1 (de) Flüssige pharmazeutische palonosetronformulierungen
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
ITRM20030196A0 (it) Uso di reagenti per la preparazione di un medicamento utile per la terapia perioperatoria in due stadi di tumori solidi.
ITRM20030572A1 (it) Uso di inibitori enzimatici di h-prune per la prevenzione ed il trattamento delle metastasi dei tumori iperesprimenti h-prune.
BRPI0516464A (pt) formulação farmacêutica, método para a preparação de um produto farmacêutico, e, uso de uma formulação farmacêutica
BRPI0313053A2 (pt) cânula para dispensar produtos fluidos
ITMI20030479A1 (it) Procedimento per la preparazione di un ciano-isobenzofurano.
ITMI20031994A1 (it) Procedimento per la preparazione di fludarabina fosfato
ITTO20030850A1 (it) Procedimento per la preparazione di 4-ammino-3,5-dicloro-benzotrifloruro.
DZ3461A1 (fr) Pro-medicaments d acides amines excitateurs.
NO20034952D0 (no) Farmasöytiske forbindelser
ITMI20030018A1 (it) Procedimento per la preparazione di composti mono-
IS6984A (is) Notkun á pýridóindólon afleiðum til framleiðslu lyfja gegn krabbameini
ITMI20030352A1 (it) Metodo per la sintesi di metiltriossorenio.
ITMI20040443A1 (it) Prpcesso per la preparazione di ..15-16-17-cheto-steroidi e loro uso nella sintesi di composti farmacologicamente attivi
ITMI20030019A1 (it) Procedimento per la preparazione di composti mono-
ITUD20030196A1 (it) Procedimento per la preparazione di dosaggi farmaceutici contenenti molteplici principi attivi.
ITRM20000433A0 (it) Uso di fibrati per la preparazione di un medicamento utile nel trattamento dell'insufficenza cardiaca congestizia.
ITMI20032417A1 (it) Composizione farmaceutica particolarmente per uso dermatologico.
ITRM20030442A0 (it) Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia.
ES1055546Y (es) Contenedor-dosificador para pastillas farmaceuticas.